SinoMab Bioscience Ltd. (HK:3681) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
SinoMab BioScience Ltd. has announced the successful first dosing of a patient in a Phase 1b clinical trial in China for their novel SM17 treatment for Atopic Dermatitis. The treatment, which targets the IL-25 receptor to modulate Type II allergic reactions, has previously shown a good safety profile in Phase I trials. The company is optimistic about SM17’s potential as a more effective treatment option for patients unresponsive to current therapies.
For further insights into HK:3681 stock, check out TipRanks’ Stock Analysis page.